Red meat consumption is associated with endogenous metabolic generation of mutagenic N-nitroso compounds (NOC) and may be implicated in causation of colorectal cancer. Assessment of a biologically relevant dose of NOCs is hampered by imperfect understanding of NOC interactions with other dietary components. This study tests the hypothesis that NOC effects upon mutational biomarkers in mouse colon may be modulated by a non-genotoxic dietrelated compound. N-methyl-N-nitrosourea (MNU) and undegraded l carrageenan (lCgN) were selected as test chemicals, representing a NOC and a non-genotoxic agent, respectively. Study end-points included (i) DNA adduct formation and (ii) metallothionein (MT) crypt restricted immunopositivity indices (MTCRII) which are considered representative of crypt stem cell mutations. Frequency and size of MT immunopositive foci as well as total number of MT immunopositive crypts were assessed. Biologically effective doses of MNU and lCgN were determined in model validation studies and the agents were then tested alone and in combination. Continuous lCgN treatment for 10 weeks induced significantly greater colonic mucosal injury than a drinking water control. In combined treatment regimens, lCgN treatment did not significantly affect MNU-induced DNA adduct formation. However, combinations of lCgN with MNU significantly increased MTCRII in excess of those induced by MNU alone. Recurrent or continuous lCgN regimens had greater interactive effects with MNU upon MTCRII than short-term lCgN treatment. This study has shown that exposure to a nongenotoxic diet-related compound (lCgN) modulates the effective NOC dosimetry for induction of MT crypt restricted immunopositivity.
Red meat consumption is associated with endogenous metabolic generation of mutagenic N-nitroso compounds (NOC) and may be implicated in causation of colorectal cancer. Assessment of a biologically relevant dose of NOCs is hampered by imperfect understanding of NOC interactions with other dietary components. This study tests the hypothesis that NOC effects upon mutational biomarkers in mouse colon may be modulated by a non-genotoxic dietrelated compound. N-methyl-N-nitrosourea (MNU) and undegraded l carrageenan (lCgN) were selected as test chemicals, representing a NOC and a non-genotoxic agent, respectively. Study end-points included (i) DNA adduct formation and (ii) metallothionein (MT) crypt restricted immunopositivity indices (MTCRII) which are considered representative of crypt stem cell mutations. Frequency and size of MT immunopositive foci as well as total number of MT immunopositive crypts were assessed. Biologically effective doses of MNU and lCgN were determined in model validation studies and the agents were then tested alone and in combination. Continuous lCgN treatment for 10 weeks induced significantly greater colonic mucosal injury than a drinking water control. In combined treatment regimens, lCgN treatment did not significantly affect MNU-induced DNA adduct formation. However, combinations of lCgN with MNU significantly increased MTCRII in excess of those induced by MNU alone. Recurrent or continuous lCgN regimens had greater interactive effects with MNU upon MTCRII than short-term lCgN treatment. This study has shown that exposure to a nongenotoxic diet-related compound (lCgN) modulates the effective NOC dosimetry for induction of MT crypt restricted immunopositivity.
Introduction
Dietary or lifestyle factors may be implicated in the 20-fold international variance of colorectal cancer (CRC) risk (1) . Consumption of red meat promotes formation and colonic excretion of genotoxic N-nitroso compounds (NOCs) (2) and is linked to CRC (3). Non-genotoxic substances from foods or beverages can modulate mutagen effects (4) and may influence the promotion phase of tumour formation (5) . Ethanol, for example, is non-genotoxic with pro-inflammatory properties (6) and may enhance NOC-induced carcinogenesis (7) . Native carrageenans are non-genotoxic (8) and are used as food additives. At high doses, native carrageenans may have pro-inflammatory properties (9EE12) and may have a role in neoplastic change (13) . Food grade l carrageenan (lCgN) is used as a thickener, emulsifier or stabilizer (14) .
Cancer risk assessment of mixtures of dietary or lifestyle toxicants is hampered by limited comprehension of chemical additive or interactive effects (15) . Robust biomarkers of early events of tumourigenesis, including DNA damage, somatic stem cell mutation and mutant clonal expansion, may facilitate mechanistic studies of dietary effects. O 6 -methyldeoxyguanosine and 7-methylguanine adduct formation has been demonstrated in human colorectal DNA (16) and provides a measure of N-nitroso compound-mediated DNA damage. O 6 -methyldeoxyguanosine is pro-mutagenic and induces characteristic GC3AT transition mutations (17) involving K-ras (18) . Mutation of K-ras is a key event of human colorectal tumourigenesis (19, 20) and may be implicated in a proportion of dietrelated cancers. Within the colon, crypt stem cells represent a primary target for genotoxic events and neoplastic transformation (21, 22) . Biomarkers of specific oncogene mutations in the stem cell fraction of morphologically normal colonic mucosa are lacking. However, frequencies and patterns of oncologically neutral mutations in colonic crypt stem cells may be assessed by an endogenous marker gene assay, such as glucose 6-phosphate dehydrogenase (G6PD) (23, 24) . Expression of the mutant marker in stem cell clonal descendants produces a phenotypic change throughout an entire crypt. Crypt fission represents a primary mechanism of clonal expansion in the colon (22) . Mutant crypt fission may generate a`patch' of two or more contiguous mutant crypts.
Persistent metallothionein (MT) overexpression within single crypts has been tested as a biomarker of colonic crypt stem cell mutation. Jasani et al. found that the frequency and time course of crypt conversion to MT immunopositivity in mice treated with dimethylhydrazine (DMH) was similar to that of the G6PD assay (25) . Cook et al. demonstrated a strong correlation between the MT and G6PD assays (r 4 0.9) in Balb/c mice treated with N-ethyl-N-nitrosourea (ENU). The MT bioassay has the advantage of use in paraffin fixed tissue sections (26) . Stable, crypt restricted immunopositivity for MT thus correlates with an established mutation marker in the mouse colon (G6PD) and is considered to result from a mutation affecting expression of the MT gene in a colonic stem cell (26) .
Preliminary studies of this project sought suitable test doses of both undegraded lCgN and the synthetic NOC N-methyl-N-nitrosourea (MNU) for the toxic effects of interest. Effects of lCgN in drinking water were assessed on colonic mucosal inflammation or injury, using a semi-quantitative histological scoring system (27) . DoseEEresponse assays of MNU were carried out against O 6 -methyldeoxyguanosine and 7-methylguanine adduct formation and MT crypt restricted immunopositivity in mouse colon. Individual and combined lCgN/MNU effects were then assessed against these mutational events. A single treatment with MNU was combined with different temporal lCgN exposures. MNU (62.5 mg/kg i.p.) was thus given alone or in combination with single or recurrent short-term or long-term continuous lCgN treatment (1 or 4% in drinking water). Indirect growth effects of dietary interventions may affect toxicological outcomes (28, 29) . To accommodate these considerations, we assessed the weight gain of individual animals and group consumption of food and fluid in different treatment categories.
Materials and methods
Chemicals and reagents lCgN (C3889) extracted from two species of seaweed Gigartina aciculaire and Gigartina pistillata was purchased from Sigma (Poole, UK). This was not food grade but is described by the manufacturer as essentially pure undegraded lCgN. MNU and dimethylsulphoxide (DMSO) were also obtained from Sigma UK. Mouse monoclonal anti-horse MT and peroxidase-conjugated swine antirabbit antibodies were obtained from Dako Ltd (High Wycombe, UK) (25, 26) . The primary mouse monoclonal antibody to MT used in the study reacts with a highly conserved immunoreactive site within the last five to seven amino acids of the N-terminus of the B domain of the MT protein. [methyl- 3 H]MNU was obtained from Amersham Biosciences (Little Chalfont, UK). This had been assessed as 99.4% pure by HPLC on a Hyperasil MOS column using a multilinear gradient of 1% glacial acetic acid in water to acetonitrile.
Animals and treatment regimes
Female adult Balb/c mice, aged 6EE8 weeks, were obtained from Harlan UK Ltd (Bicester, UK). Animals were divided into groups of 5 or 10 and ear punched. Animal groups were placed in stainless steel wire cages, coded according to treatment. All animals were housed in a clean air-conditioned environment (23 AE 2 C), with a 12 h light/dark cycle, had unlimited access to AIN-76 carcinogen-and antioxidant-free diet (Harlan UK Ltd) and were weighed each day. Consumption of water, lCgN solution and AIN-76 diet was assessed by careful weighing of fluid and food containers for each group, each day. Fluid volume intakes were assessed by application of the appropriate conversion factor (1 g water and 1 and 4% lCgN solutions 1.0, 0.91 and 0.71 ml, respectively, determined by prior measurement). All assessments of inflammatory mucosal injury, adduct formation and MT immunopositive crypt indices were blind to treatment. Codes were broken only on completion of the analysis.
Assessment of pro-inflammatory effects of lCgN in mouse colon Three groups of 5 mice received drinking water containing 0 (control), 1 or 4% lCgN continuously for 10 weeks. Colons were retrieved for gross and histological examination on completion of the treatment.
Assessment of mucosal gross morphology and histology
Mouse colons were opened longitudinally along the full length and faecal material removed with forceps. Colons were pinned to a cork mat, examined at 40Â magnification under a dissecting microscope and morphological changes including redness or ulceration were recorded. Colons were theǹ Swiss-rolled' on a cork mat, placed in plastic cassettes, fixed in neutral formal-buffered saline for 48 h and embedded in paraffin blocks. Sections of 4 mm were cut at 10 levels 100 mm apart throughout the block and stained with haematoxylin and eosin for histological assessment of crypt loss, crypt hyperplasia or inflammation. Light microscopy of the entire length of all colons was carried out using a Zeiss Axiovert microscope, by two investigators (E.T.D. and W.G.McC.) working independently. Consensus scores were given as results. Histological scoring of crypt loss, hyperplasia/distortion and inflammation was carried out as described by Cooper et al. (27) and was blind to treatment category. The total number of crypts were counted in one section per block and the percentage of crypts affected by injury, inflammation or hyperplasia/distortion were scored as follows: score 1, 1EE25%; score 2, 26EE50%; score 3, 51EE75%; score 4, 76EE100% (27 Isolation of DNA Each colon was homogenized in 1 ml of water containing 10 mM EDTA, 1% SDS and 0.1% proteinase K and incubated at 37 C for 2 h. The RNA content of the isolated material was estimated from peaks due to guanosine and adenosine in the HPLC analysis and amounted to~5%. Homogenates were extracted with phenol:chloroform (1:1) three times, the DNA precipitated by addition of ethanol, redissolved, treated with RNase A T and further extracted twice with chloroform:isoamyl alcohol (24:1) (30). DNA was precipitated with ethanol, washed with ethanol and ether, dried and redissolved in 0.5 ml of water.
Analysis of DNA DNA was hydrolysed to nucleosides by successive treatment, all at 37 C, with: (i) 3 ml DNase I (Roche, 50 U/ml) 10 ml buffer (0.5 M Tris, pH 7 0.5 M MgCl 2 ) for 17 h; (ii) 3 ml snake venom phosphodiesterase (Sigma Type II, 5 U/ ml) 80 ml buffer (0.5 M Tris, pH 9) for 7 h; (iii) 3 ml alkaline phosphatase (Sigma Type III, 300 U/ml) for 17 h. Hydrolysis appeared complete. Incomplete hydrolysis would lead to tritium activity coming straight through the column (before the deoxycytidine peak). Negligible activity was observed in this region. An aliquot of 5 mg O 6 -methyldeoxyguanosine (Sigma) was added as a marker and the mixture was analysed by HPLC on a Nucleosil ODS column (5 mm, 250 Â 4.6 mm) with a water (A 0.05 M ammonium formate, pH 6) to methanol linear gradient (10 min A, then to 30% methanol in 35 min at 0.7 ml/min). The column separated deoxycytidine (15EE18 min), thymidine (33 min), deoxyguanosine (35 min), deoxyadenosine (44 min) and O 6 -methyldeoxyguanosine (50 min). The retention times of 7-methylguanine and 3-methyladenine were 32 and 43 min, respectively. Fractions were collected and assayed for UV absorbance and tritium activity. No other methylated substances are known to co-elute with 7-methylguanine or O 6 -methyldeoxyguanosine. Absorbance figures were used in the calculation of amounts of each nucleoside present. Tritium activity was counted in fractions with retention times of 23EE62 min, where methylated products might be expected. Counting efficiency was 42%. Background activities in unlabelled and labelled samples were 10 and 13EE17 c.p.m., respectively. Samples were analysed individually. Analysis of methylated DNA was against standards obtained by treating calf thymus DNA with [methyl-
3 H]MNU, as previously described (31). 7-Methylguanine and the promutagenic adduct O 6 -methyldeoxyguanosine were assayed in total DNA and expressed as adducts/10 6 nt.
MNU doseEEresponse study versus colonic crypt MT immunopositivity
Five groups of 5 mice received either a single injection of distilled water only, DMSO (5%) (vehicle) only or 62.5, 125 or 250 mg/kg MNU dissolved in DMSO vehicle by single i.p. injection. AIN-76 diet and drinking water were permitted ad libitum. OECD guidelines were observed and animals were checked daily for signs of pain or distress (28, 29) . At the dose of 250 mg/kg, MNU induced weight loss and lethargy 7 days after injection. This group of 5 animals was terminated for humane reasons 1 week after treatment. All other mice were killed by cervical dislocation 10 weeks after MNU injection. Their colons were removed, opened, cleaned and Swiss-rolled, fixed in 10% neutral-buffered formalin and processed to paraffin blocks, as previously described (26) .
Assay of colonic crypt mutations by metallothionein immunohistochemistry
Paraffin-embedded sections (4 mm thickness) were cut at 10 levels (L1EEL10), 100 mm apart through the Swiss-rolled colon. One section from each level was stained using a standard indirect immunoperoxidase technique for MT, as previously described (26) . Briefly, endogenous peroxidase activity was blocked by placing slides in methanol with 3% hydrogen peroxide for 30 min. Slides were incubated with an anti-metallothionein primary antibody (mouse anti-horse monoclonal E9, isotype IgG1, 100 ml/slide) (DAKO Ltd, Ely, UK) at a dilution of 1 in 1000 at 4 C overnight. This antibody recognizes both isoforms of the MT protein and is directed against a highly conserved epitope. Negative control sections were incubated either in the absence of antibody, in normal mouse serum (1:1000) or with an irrelevant antibody of the same IgG subclass (1:1000) (IgG1, Dako catalogue product code X0931). These were consistently negative. Positive control sections were of mouse colon previously treated with 250 mg/kg ENU, which induces MT immunopositive crypts (26) . Primary antibody was carefully washed off with PBS. Secondary antibody (rabbit anti-mouse immunoglobulin; Dako catalogue product code P0161) was added (100 ml per slide) and incubated at room temperature for 1 h. Sections were then washed, incubated with the chromogen 3,3
H -diaminobenzidine tetrahydrochloride, counterstained with Harris haemotoxylin and mounted with Distrene Plasticiser Xylene as previously described (26) . One additional section from levels 1, 5 and 10, respectively, were also stained with haematoxylin and eosin. Sections from levels 1 and 10 were used to confirm comparability of the size of the colon section examined between levels and for assay of total crypt number. The number of crypt profiles in one median section per mouse was counted by microscopy incorporating an eyepiece graticule, along a grid of parallel lines 700 mm apart. The number of crypts per section was multiplied by the number of levels studied (n 10) to determine the total crypt count per mouse, as previously described (26) . Dark brown staining crypts against a haematoxylin background were recorded as positive in transverse or longitudinal section through the crypt lumen. The numbers of adjacent mutant crypts in immunopositive mutant patches were counted and recorded as doubles, triples or greater. Only wholly involved MT immunopositive crypts or patches were regarded as biomarkers of stem cell mutational events. Each single MT immunopositive crypt or patch was considered to represent a single mutant focus. The frequency of MT immunopositive foci and total number of MT immunopositive crypts were expressed per 10 4 crypts. The number of MT immunopositive crypts within each positive focus was also assessed.
Dose selection for combined treatment studies
Statistical modelling was based on previous work using DMH, with or without 6% undegraded carrageenan in the diet (32) . That study showed an~80% increase in experimental colonic tumour formation with the combination treatment compared against DMH alone (32) . In the present study, 62.5 mg/kg MNU induced sufficient crypt mutations (see Results) to provide the statistical power for detection of an additive or interactive lCgN effect of this magnitude, in 10 animals per group.
Combined treatment studies Assessment of effects of lCgN on MNU adduct formation. Three treatment groups of 5 mice each received a single i.p. dose of 50 mCi [methyl-
3 H]MNU with 1.25 mg unlabelled MNU, representing an exposure dose of 62.5 mg/kg with either distilled drinking water only or 1 or 4% lCgN in the drinking water. MNU was administered in 5% DMSO i.p. after 5 days treatment with lCgN. Four control groups of 2 mice each received drinking water only or 1 or 4% lCgN in the drinking water or 5% DMSO vehicle only i.p. Mice were killed 24 h after MNU treatment and colons retrieved for assay of adduct formation by the methods outlined above.
Assessment of lCgN effects on MNU-induced colonic crypt mutation. Eleven groups of mice received no MNU, MNU alone or in combination with 1 or 4% lCgN, as follows ( Figure 1 ): Group 1, drinking water for 10 weeks; Group 2, a single i.p. injection of DMSO, then drinking water for 10 weeks; Group 3, continuous 1% lCgN for 10 weeks; Group 4, continuous 4% lCgN for 10 weeks; Group 5, 62.5 mg/kg MNU i.p. and drinking water for 10 weeks; Group 6, 62.5 mg/kg MNU i.p. and 1% lCgN for 7 days during week 1, then drinking water until 10 weeks; Group 7, 62.5 mg/kg MNU i.p. and 4% lCgN for 7 days during week 1, then drinking water until 10 weeks; Group 8, 62.5 mg/kg MNU i.p. and three 7 day treatments with 1% lCgN during weeks 1, 4 and 7, with drinking water given between and after lCgN treatments until 10 weeks; Group 9, 62.5 mg/kg MNU i.p. and three 7 day treatments with 4% lCgN during weeks 1, 4 and 7, with drinking water given between and after lCgN treatments until 10 weeks; Group 10, 62.5 mg/kg MNU i.p. and continuous 1% lCgN treatment until 10 weeks; Group 11, 62.5 mg/kg MNU i.p. and continuous 4% lCgN treatment until 10 weeks.
In the combined regimens, MNU was administered after the first 5 days of lCgN treatment. Assays of MT immunopositive crypts were carried out by two assessors (E.T.D. and H.B.), working independently in Belfast and Cambridge, respectively, and were blind to treatment category. Observer variance was checked by each assessor re-scoring 90 randomly selected tissue sections. Study codes were broken and results compared on completion of the observer variance assessment.
Animal welfare
Welfare considerations were in strict accordance with OECD guidelines (28, 29, 33) .
Data analysis
Effects of lCgN alone on histological scores of mucosal injury were assessed by one-way between-group ANOVA. Effects of MNU alone or with lCgN upon 7-methylguanine and O 6 -methyldeoxyguanosine adduct formation were assessed using ANOVA for a factorial experimental design. Adduct levels were expressed per 10 6 nt and are described as the mean AE SD. MT immunopositive crypt indices were expressed per 10 4 total crypts. In MNU doseEE response studies, MT immunopositive crypt data were log transformed and assessed by a probability plot of residuals to provide a normal distribution. Transformed data were analysed by one-way between-groups ANOVA. Formation of MT immunopositive patches was corrected for the confounding effect of physiological crypt fission. For each animal, the value for total number of MT immunopositive patches was divided by the frequency of MT immunopositive foci.
Serial animal weight data were available in individual mice. Incremental weight gain between study start and completion was calculated as a percentage increase over original weight for individual mice in each treatment group. Most study animals achieved 120% of their original weight by study completion. A Cox proportional hazards model was used to assess any time differences for initial achievement of 120% of original body weight between treatment groups. The weight index was calculated as the weight at study completion relative to the weight at study start, expressed as a percentage. Between-group differences in weight index were assessed by one-way ANOVA. Descriptive statistics applied to weight index were expressed as means AE SD. Group data were available for consumption of food and fluid, which were assessed in g/kg body wt or ml/kg body wt, respectively. Descriptive statistics were expressed as the mean. To achieve a normal distribution, MT immunopositive crypt indices from each MNU/lCgN treatment group were log transformed and assessed by a probability plot of residuals. Transformed data were analysed by ANOVA. Duncan post hoc tests were applied to assess differences between specific treatment regimens. Any correlation between colonic crypt mutational indices was investigated by Pearson's product moment coefficient. Fig. 1 . Treatment strategies for assessment of lCgN/MNU interactive effects upon MT immunopositive crypt indices. All lCgN treatments began on day 1. Timing and duration of 1 and 4% lCgN treatment are represented by light and dark shaded areas, respectively. In groups 8 and 9, each 7 day interval of lCgN exposure was followed by a 2 week`washout' interval of drinking water only, without lCgN intake. MNU (62.5 mg/kg) was administered as a single i.p. injection, on day 5.
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The SPSS for Windows (version 11) program was used for statistical analysis (SPSS Inc., Chicago, IL).
Results

Model validation studies: individual test agents given alone
Effects lCgN treatment on stool consistency, gross mucosal morphology and histology. Fifteen female Balb/c mice received drinking water only or continuous 1 or 4% lCgN in the drinking water for 10 weeks. All mice in the water-only treatment group had solid stools throughout the 10 week study interval. Stools became semi-soft after 32 days of continuous 1% lCgN. Mice receiving continuous 4% lCgN developed stools of this consistency within 1 week and soft semi-liquid stools after 11 days. Redness was found in the proximal 1/3 of the colon in all mice receiving 1 and 4% lCgN. In 3 mice of the 4% lCgN group, redness extended throughout the proximal 2/3 of the colon. No abnormalities were observed in the water-only treatment group. One-way ANOVA demonstrated significant between-group differences in crypt loss, mucosal inflammation and crypt hyperplasia/distortion scores (Table I and Figure 2 ).
MNU doseEEresponse assay against DNA adduct formation and MT crypt immunopositivity. A mean AE SD of 1.32 AE 0.24 mmol DNA phosphate, corresponding to~0.50 mg DNA, was isolated from each mouse colon. Administration of 62.5 or 125 mg/kg MNU induced dose-related formation of 7-methylguanine and O 6 -methyldeoxyguanosine adducts in mouse colon, in excess of the distilled water or DMSO-treated control groups (P 5 0.001; Table II) . A further batch of 20 mice was treated with these regimens. Colons were retrieved after 10 weeks for assay of MT immunopositive (mutant) crypt indices ( Figure 3) . One way ANOVA indicated significant betweengroup differences in the frequency of immunopositive foci (P 5 0.001), total number of immunopositive crypts (P 5 0.001) and numbers of patches of !2 immunopositive crypts (P 0.008). MNU showed a doseEEresponse effect upon adduct formation and total number of immunopositive crypts (Tables II and III) .
Combined treatment studies Effects of short-term lCgN treatment upon MNU-induced adduct formation in mouse colon. Colons were retrieved 24 h after MNU treatment for assay of adduct levels. Levels of 7-methylguanine and O 6 -methyldeoxyguanosine isolated from colonic DNA after administration of 1 or 4% lCgN with MNU were not significantly different from those of MNU alone (Table II) .
Effects of treatment regimens on food, fluid intake and body weight. Eleven treatment groups of mice (n 90) received lCgN alone or in combination with MNU (62.5 mg/kg i.p.) for assay of MT immunopositive crypt indices (Figure 1) . Group values for fluid and food intake for these studies are shown (Table IV) . The rate of weight gain was compared between groups by assessment of the time from the start of the study to initial gain of 120% of the original body weight. Values for mean weight index were also compared between treatment groups at study completion. Neither lCgN nor MNU treatment, whether administered alone or in combination, was associated with a significant delay of weight gain. No significant differences in group weight index were observed at study completion (Table IV) 4 crypts. Groups 9 and 11 (MNU and three 7 day treatments with 4% lCgN or continuous 4% lCgN) had mean frequencies of MT immunopositive foci of 36.3EE37.3 AE 9.6EE9.7, which overlapped subsets C and D (Figure 4 ). Differences between subsets were statistically significant (P 5 0.001).
One way between-groups ANOVA showed that combined lCgN/MNU regimes induced significantly greater total numbers of MT immunopositive crypts than MNU alone or treatments lacking MNU. The Duncan post hoc test identified the same four homogeneous treatment subsets (AEED) as previously shown in analysis of frequency of MT immunopositive foci. These subsets showed significant incremental differences in total number of MT immunopositive crypts. One-way ANOVA demonstrated significant between-group differences in MT immunopositive patch formation (P 5 0.001) ( Figure 5 ). Over 95% of patches involved only two contiguous MT immunopositive crypts. Mean patch frequency relative to frequency of MT immunopositive foci was 10.08 AE 0.4 for MNU alone versus 13.4 AE 0.6 for all combined lCgN/MNU treatment groups.
Assessment of inter-observer variance of MT immunohistochemistry was carried out. Mean AE SD frequencies of MT immunopositive foci for observers H.B. and E.T.D. were 9.9 AE 8.1 versus 10.6 AE 8.1 mutant foci/10 4 crypts, respectively, representing inter-observer variance of 510%. Total crypt numbers counted by observers H.B. and E.T.D. were 31 525 AE 6108 and 31 683 AE 5550, respectively.
Discussion
Establishing disease causality of any combination of dietary chemicals may be contingent upon knowledge of individual effects and elucidation of additive or interactive mechanisms. The present study assessed lCgN and MNU as model pro-oxidant and genotoxic chemicals alone and in combination against disease-relevant end-points in mouse colon. Undegraded lCgN was given at target organ toxic doses (34) within the limits of the OECD guidelines (29) . We found that continuous oral lCgN treatment (1 or 4%) was associated with Values shown are means AE SD. Continuous 1 or 4% lCgN induced greater hyperplasia (P 5 0.001) and inflammation scores (P 0.05 and 0.008, respectively) than the distilled drinking water control. 4% lCgN induced greater crypt loss than 1% lCgN (P 0.03) or drinking water (P 0.002) (ANOVA).
laxation, redness of the proximal colonic mucosa and histological evidence of inflammatory mucosal injury. All parameters of inflammation, crypt loss and crypt hyperplasia were significantly increased in different colonic regions in lCgN-treated mice. Dose-dependent effects of MNU upon DNA adduct formation and MT immunopositive crypt indices were then tested in mouse colon. Like other biomarkers based on mutagen-induced phenotype alteration (23, 35, 36 ) the assay of permanent crypt restricted MT immunopositivity is used to infer somatic mutations in 
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intact tissue. The MT assay has been endorsed as an in vivo biomarker of colonic crypt stem cell mutation (25, 26) by quantitative validation against the G6PD system (26), which links to specific G6PD gene mutations in crypt stem cells (24) .
On this basis, stable, crypt restricted immunopositivity for MT is considered to result from a mutation affecting expression of the MT gene in a colonic stem cell (26) . After such an event, clonal stabilization, elimination of any confounding MT immunopositive transitory cells by homeostatic turnover and permanent re-population of the crypt by MT immunopositive stem cell progeny occurs over an interval of 6 weeks (25). These temporal events are similar to those observed after G6PD mutation in crypt stem cells (37) . To accommodate these events, the study design incorporated a minimum interval of 10 weeks between MNU treatment and MT assay. In this study MNU treatment induced dose-dependent effects upon adduct formation and MT crypt immunopositivity. (a) (b) Values shown are means AE SD. 62.5 or 125 mg/kg MNU induced a greater mutation frequency or total mutation load than the water or DMSO control (ANOVA, P 5 0.001). Mutant patch formation was greater with 125 mg/kg MNU versus control. Group values only were available for fluid or food intake. Individual animal weights were available. The weight index was calculated as the weight at study completion relative to weight at study start, expressed as a percentage.
Values shown are means of group fluid or food intake and means AE SD for weight index. No between-group differences in weight index were found (ANOVA).
A principal objective of this study was to investigate any additive or interactive effects of a non-genotoxic diet-related chemical upon NOC-induced mutational events. Human exposure to carrageenan is variable (38) , occurring by consumption of foods like processed meat (39) , bread (40) , sauces (41) and desserts (14) . The present study modelled this consumption variance by regimens of different lCgN dose and continuity of exposure, alone or in combination with a single treatment with 62.5 mg/kg MNU. Treatment with continuous lCgN alone was pro-inflammatory in this study but had no demonstrable effects on MT immunopositive crypt indices. Hence, any oxidative DNA modifications due to lCgN treatment were not converted to MT immunopositive crypt foci. Short-term treatment with 1 or 4% lCgN had no effect upon 7-methylguanine and O 6 -methyldeoxyguanosine adduct levels induced in colonic DNA by 62.5 mg/kg MNU. In contrast to the lack of any effects of lCgN alone, we found that all patterns of lCgN intake in combination with MNU induced greater MT immunopositive crypt indices than MNU alone. Significant effects upon MT crypt immunopositivity were observed after shortterm treatment (7 days) with 1 or 4% lCgN with MNU. Further significant incremental increases in MT immunopositive indices were induced by repeat short-term or continuous 1% lCgN treatments. Treatment regimes were well tolerated and between-group differences in weight gain were within OECD recommended limits (28, 29) . It appears unlikely that indirect effects of treatment combinations or inter-observer variance of MT immunohistochemistry, which was always 510%, could account for observed outcomes. Effects of combined lCgN/MNU regimes upon crypt stem cell mutational frequency appeared to be less with 4% than with 1% lCgN, although differences were not statistically significant. These data could result from a dose saturation effect for lCgN, possibly as a result of excessive tissue injury, cell death, inhibition of healing or other mechanism. Since lCgN treatment alone was ineffective against MT immunopositive crypt indices, effects with MNU were considered interactive rather than additive (42) .
Interactions between genotoxic and non-genotoxic agents may affect physico-chemical properties of mutagenic substances, efficacy of DNA repair or other mechanisms (43) . Carrageenans enhance tissue expression of nitric oxide (9), which effectively inhibits O 6 -alkylguanine-DNA alkyltransferase, the DNA repair enzyme responsible for removal of the pro-mutagenic adduct O 6 -methyldeoxyguanosine (44) . This mechanism could promote somatic mutation (45) . Increased cell proliferation induced by carrageenan (46) could also enhance mutability (47) . In a state of sustained lCgN-induced inflammation, the pro-inflammatory cytokine MIF could inhibit p53-mediated elimination of cells bearing irretrievable DNA damage (48) , thus enhancing mutation. However, further work is required to determine the precise molecular mechanisms of the lCgN/MNU interaction.
Non-genotoxic chemicals may promote clonal expansion by crypt fission, leading to development of`patches' of two or Fig. 4 . Effects of treatment regimes on the frequency of MT immunopositive crypt foci. Treatment groups: 1, water only; 2, DMSO only; 3, continuous 1% lCgN only; 4, continuous 4% lCgN only; 5, 62.5 mg/kg MNU only; 6, MNU 1 Â 7 day cycle of 1% lCgN; 7, MNU 1 Â 7 day cycle of 4% lCgN; 8, MNU 3 Â 7 day cycles of 1% lCgN; 9, MNU 3 Â 7 day cycles of 4% lCgN; 10, MNU continuous 1% lCgN; 11, MNU continuous 4% lCgN. Error bars denote AE1.0 SD. Significant differences have been identified between four homogeneous subsets, namely: groups 1EE4 (no MNU); group 5 (62.5 mg/kg MNU alone); groups 6 and 7 (62.5 mg/kg MNU 1 Â 7 day exposure to 1 or 4% lCgN); groups 8 and 10 (62.5 mg/kg MNU 3 Â 7 day exposure of 1% lCgN or continuous 1% lCgN). Differences between each of the subsets are statistically significant (P 5 0.001). Groups 9 and 11 (62.5 mg/kg MNU 3 Â 7 day treatments of 4% lCgN or continuous 4% lCgN) overlapped the third and fourth subsets. Dietary interactions and colon tumourigenesis more adjacent mutant crypts (23) . After mutagen treatment, physiological crypt fission promotes development of mutant patches in proportion to the mutation frequency (37) . The combined lCgN/MNU regimens in the present study, induced significantly greater MT immunopositive patch formation than MNU alone. To assess any promotional effects of lCgN upon MT immunopositive patch formation in excess of that due to physiological fission, we calculated patch formation as a percentage of the frequency of MT immunopositive foci. This parameter was considered representative of mutation frequency. Values were higher with combined lCgN/MNU regimens than with MNU alone. These data together with the morphological observations strongly suggest that lCgN induces crypt fission, resulting in progression of a higher proportion of single MT immunopositive crypt mutations to patches. This mechanism may contribute to the increased total number of immunopositive crypts associated with combined lCgN/MNU regimens.
Inconsistent opinions pertaining to health effects of carrageenan (14, 49) underline the need for additional data. The present study shows that undegraded lCgN enhanced the effect of a synthetic N-nitroso compound upon MT crypt immunopositivity in mouse colon. Synergy of toxic effects in short-term, high dose studies, however, does not necessarily reflect interactions at lower concentrations, commensurate with human exposures. Hence, accurate human intake data pertaining to carrageenans and N-nitroso compounds are required. In addition, further detailed studies are indicated to determine any lCgN interaction threshold, the magnitude of interactive effects, doseEEresponse effects and saturation levels and their relevance to human exposure.
